Navigation Links
Biocept, Inc. Announces CEO and Director Appointments
Date:10/6/2008

SAN DIEGO, Oct. 6 /PRNewswire/ -- Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, announced today the appointment of Stephen M. Coutts, Ph.D. as CEO, President and Director and the appointment of Edward A. Dennis, Ph.D., as Director. Biocept also announced the resignation of its former CEO, President and Director, Gordon F. Janko.

"We are pleased to welcome Dr. Coutts, a highly regarded professional in our field, and believe he is a good fit with our development strategy," said Claire K.T. Reiss, Chairman of the Board. "In addition, we are honored to add Dr. Dennis to the Board and look forward to benefiting from his extensive experience and perspective. On behalf of the Biocept Board of Directors, I would also like to thank Mr. Janko for his contributions during the five years that he led Biocept," Ms. Reiss added.

"I am delighted to join Biocept at this critical time and look forward to continuing to develop and grow this exciting technology," said Dr. Coutts.

Dr. Coutts has 30 years of experience in the pharmaceutical and biotechnical industries. He was most recently Director of Pharmaceutical Development at Cypress Bioscience, Inc. and a principal at Alembic Biotech Consultants. He was previously President and COO at Triad Therapeutics, Inc. and spent 11 years as Executive Vice President for R&D at La Jolla Pharmaceutical. Dr. Coutts holds a BS in Chemistry from San Diego State University, a Ph.D. in Biochemistry from Harvard University and an MBA from New York University.

Dr. Dennis is Distinguished Professor of Chemistry and Biochemistry and of Pharmacology in the School of Medicine at the University of California at San Diego (UCSD). He is currently Editor-in-Chief of the Journal of Lipid Research and has been named a Fellow of the American Association for the Advancement of Sciences. Dr. Dennis serves on the Scientific Advisory Board and Board of Directors of several private and public companies. He received his BA from Yale University and a Ph.D. from Harvard University.

About Biocept

Biocept, an emerging biotechnology leader, engineers novel microfluidic devices that provide the foundation for a new class of diagnostic assays. Biocept is based in San Diego, California, a major center for academic and industrial life sciences research. Founded in 1997, the company is privately held and draws on a team rich in experience in life science. Its CLIA clinical laboratory is accredited by the College of American Pathologists and holds licenses in California and other states as required.


'/>"/>
SOURCE Biocept, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Glemser Announces New Labeling Solution: SPL for DCM Addresses New SPL Release 4 Requirements
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Connecticut Technology Council Announces UHY LLP Tech Top 40 Winners
4. Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
5. SyntheMed Announces New Management Appointments
6. Alba Therapeutics Corporation Announces Promotions
7. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
8. 23andMe Announces Breast Cancer Initiative
9. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
10. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
11. Synthetech Announces New Director of Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):